Antithrombotic and Anti-Inflammatory Effects of Fondaparinux and Enoxaparin in Hospitalized COVID-19 Patients: The FONDENOXAVID Study.
Giuseppe CardilloGiuseppe Vito ViggianoVincenzo RussoSara MangiacapraAntonella CavalliGiampiero CastaldoFederica AgrustaAnnamaria BellizziMaria AmitranoMariateresa IannuzzoClara SaccoCorrado LodigianiAndrea FontanellaPierpaolo Di Micconull nullPublished in: Journal of blood medicine (2021)
Increased levels of fibrinogen and D-dimer in patients with confirmed COVID-19 have been reported in several studies. Our results showed that anti-inflammatory effects of fondaparinux and enoxaparin after 3 weeks of prophylactic treatment were similar when levels of fibrinogen and D-dimer were considered. Furthermore, levels of CRP showed a decrease in patients treated with enoxaparin and fondaparinux, although the decrease in the fondaparinux group seems to be more relevant.